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ScienceDirectGenomic studies have provided key insights into how cancers
develop, evolve, metastasize and respond to treatment.
Cancers result from an interplay between mutation, selection
and clonal expansions. In solid tumours, this Darwinian
competition between subclones is also influenced by
topological factors. Recent advances have made it possible to
study cancers at the single cell level. These methods represent
important tools to dissect cancer evolution and provide the
potential to considerably change both cancer research and
clinical practice. Here we discuss state-of-the-art methods for
the isolation of a single cell, whole-genome and whole-
transcriptome amplification of the cell’s nucleic acids, as well
as microarray and massively parallel sequencing analysis of
such amplification products. We discuss the strengths and the
limitations of the techniques, and explore single-cell
methodologies for future cancer research, as well as diagnosis
and treatment of the disease.
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Introduction
Cancer is a disease caused by changes to the DNA,
whereby the cancer genome is shaped by the interplay
of processes of DNA damage and repair, cellular selection
and clonal expansions [1,2]. Tumour evolution is classi-
cally thought of as a series of clonal expansions that are
each triggered by new driver mutations conferring a
selective advantage [3,4], hence ‘new’ cells undergo
Open access under CC BY license.Current Opinion in Genetics & Development 2014, 24:82–91 Darwinian evolution, very much like how species develop
[5,6]. Over the past decades, we have learnt much about
how cancers develop from studying their genomes, most
notably through the introduction of massively parallel
sequencing. Comparison of cancer samples from different
sites or different time points is increasingly painting a
picture of cancers undergoing branching evolution, result-
ing in competition between different subclones [7–13]. In
solid tumours, this picture is further complicated by a
topological component [8,14], with potentially different
selection forces operating at different locations of the
tumour.
Most current large-scale cancer genome sequencing stu-
dies use DNA extracted from millions of cells. The
resulting genome sequences therefore contain intermixed
sequences from different tumour clones, as well as from
admixed normal cells. Computational methods can deter-
mine which mutations are clonal (present in all tumour
cells) and which are subclonal [15]. In addition, by ana-
lyzing point mutation and copy number data further with
bioinformatics algorithms, phylogenetic trees of different
tumour subclones can be inferred [12]. Although these
methods provide important information on the genomes
of distinct cell populations within the tumour, the num-
ber of tumour cell populations they can disentangle is
limited, and inferring rare subclonal populations remains
difficult.
Recent advances have made it possible to profile the
genomes of single cells. The isolation of single cancer
cells, followed by amplification of the DNA and array
profiling or next-generation sequencing (Figure 1), opens
avenues to study tumour subclonal architecture and
tumour evolution in unprecedented depth. Here, we
provide an overview of current methods to profile gen-
omes of single cells. We discuss their strengths and
limitations and the perspectives they offer for cancer
research and therapy monitoring.
Isolation of individual cancer cells
To isolate single cells from solid tumours, two main
approaches have been developed. The first method
exploits the precision of modern flow cytometry to sort
nuclei from single cells [16,17]. Tissue-cubes of
1 mm3, cut off a (frozen) solid tumour, are teased apart
in cell lysis buffer, containing DAPI, a fluorescent DNA-
intercalator, and the resulting single nuclei are flow-
sorted based on DNA content. This technique provides
the advantage of allowing identification and isolation of
tumour subpopulations on the basis of ploidy [16,17].
Although the cytoplasm is lost, extensions to analyses ofwww.sciencedirect.com
Single-cell genomics Van Loo and Voet 83
Figure 1
CTCs
Bone marrow aspiration
from the iliac crest
Liquid biopsySolid tumour tissue
following surgery
Single-cell isolation  from:
site of primary tumour blood
vessel
driver mutation
passenger mutation
Future perspectives for cancer research and treatment
overt metastases
most recent common ancestor
subclone
DTCs
distant organs
(b)
(e)
(d)
(c)
(a)
Whole-genome amplification (Figure 2) or whole-transcriptome amplication  (Figure 4)
Genomic and transcriptomic profiling of single cells using 
microarrays and next-generation sequencing (Figure 3; Figure 4)
Current Opinion in Genetics & Development
Single-cell analysis of the cancer genome. (a) Cancers arise due to the acquisition of driver mutations resulting in successive clonal expansions of
nascent tumour cells. Driver mutations that occur after the emergence of a most recent common ancestor will give rise to tumour subclones. Solid
tumours also shed cells in a patient’s blood stream (circulating tumour cells or CTCs) and cells disseminating to distant organs (disseminated tumour
cells or DTCs), which may cause overt metastases. (b) To study tumour evolution and intra-tumour genetic heterogeneity, individual tumour cells can
be isolated using a variety of techniques. Furthermore, CTCs can be isolated from peripheral blood, and DTCs from the bone marrow, a frequent
homing-niche of DTCs. (c) Following isolation, single cells are lysed and their DNA or RNA is amplified using whole-genome amplification (WGA) or
whole-transcriptome amplification (WTA) techniques, respectively. (d) The WGA and WTA products can be profiled using microarray or massively
parallel sequencing platforms, (e) providing important perspectives for future cancer research and cancer treatment.the transcriptome per se are possible [18]. However, this
approach also entails limitations. In particular, micronu-
clei may be lost. Micronuclei are not merely by-products
from genomic instability but are likely prone to DNA-
replication stress and further DNA-mutational processes
[19] and therefore may be important players in tumour
evolution.
A second method disperses the tissue from fresh solid
tumour biopsies in a single-cell suspension, using enzy-
matic treatments, including, for example, collagenases
[20]. Intact individual cells can subsequently be isolated
using (mouth-controlled) pipetting, modern cell-sorting
or microfluidics systems with or without applying
immunocytochemistry. Microfluidics devices provide
the advantage that in addition to capturing individual
cells, they also provide nanoliter reaction chambers towww.sciencedirect.com further process the nucleic acids of multiple individual
cells in parallel under highly standardized conditions at
significantly reduced reagent costs. Both of the above
technologies have the disadvantage that precise topolo-
gical information about the cell is lost, which can be
overcome by using laser capture microdissection from
fixed tissues or cryosections. However, capturing a full
cell or nucleus can be problematic [21].
Solid tumours also shed cells in a patient’s blood stream
(circulating tumour cells or CTCs) and cells disseminat-
ing to distant organs (disseminated tumour cells or DTCs)
(Figure 1). DTCs can remain dormant over a prolonged
period of time following resection of the primary tumour,
before giving rise to overt metastases [22]. Investigating
CTCs and DTCs is important not only for understanding
tumour evolution and progression, but also as liquidCurrent Opinion in Genetics & Development 2014, 24:82–91
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Whole-genome amplification methods. WGA-methods can be classified into (a) multiple displacement amplification (MDA), (b) PCR-based
technologies, and (c, d) methods combining displacement amplification with PCR. (a) MDA is an isothermal reaction using DNA polymerases with
strand displacement activity, for example, the bacteriophage phi29 polymerase. Following random priming, DNA is synthesized in the 50 to 30 direction.
When the 30 end of an extending string of nucleotides reaches the 50 end of the adjacently primed string, it displaces the latter resulting in new single-
strand DNA template for displacement amplification [30,79,80]. (b) Primer extension pre-amplification (PEP)-PCR uses oligos consisting of 15 bases
of complete degenerate sequence [81]. DNA is amplified using permissive thermocycling with increasing annealing temperatures. Degenerate-
oligonucleotide primed (DOP)-PCR applies hybrid oligos containing degenerate and defined sequence [82]. DOP-PCR is usually carried out in two
stages, starting with thermocycling at low annealing temperature (semi-random priming), followed by PCR at high annealing temperature (non-random
priming). In linker adaptor (LA)-PCR, single-cell DNA is first shred, then adaptors with universal sequence are ligated to the DNA ends, and the
universal sequences are used for PCR amplification [83]. (c) Following multiple rounds of displacement pre-amplification using hybrid oligos of
degenerate and universal sequence, PCR-ready amplicons are generated (e.g. PicoPlex [84]). (d) Multiple Annealing and Looping-Based Amplification
Cycles (MALBAC) [26]. During multiple rounds of displacement pre-amplification using a specific oligo design, looped DNA molecules are generated
which are refractory to further pre-amplification. Subsequently, these DNA-loops are amplified using PCR.
Current Opinion in Genetics & Development 2014, 24:82–91 www.sciencedirect.com
Single-cell genomics Van Loo and Voet 85
Figure 3
most recent common ancestor
subclone
Single-cell isolation
Tumour su bclonal evolution and architectu re
...GATTTTGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGTTGTCTGGATCCATTTTGTGGATGGT...
Reference genome sequence
TTTTGGTCTAGCTACAGAGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGT
TGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTT CGAACAGTTGT
AGCTACAGAGAAATCTCGATGGTGTGGGTCCCATCAGTTTGAACAGTTGTCTGGAT
TGAAATCTCGATGGAGTGGGTCCCATCAGTT CGAACAGTTGTCTGGATCCATTTTG
AAATCTCGATGGTGTGGGTCCCATCAGTTTGAACAGTTGTCTGGATCCATTTTGTG
CTCGATGGAGTGGGTCCCATCAGTT CGAACAGTTGTCTGGATCCATTTTGTGGATG
Detection of single nucleotide mutation
Genuine mutation50-base reads WGA-artefact Genuine SNP
Referen ce genome sequence
Detection of structural alterations
Genuine duplicationDiscordant read-pair resulting
from chimeric WGA-molecule
Filtering, e.g. by data integration:
Copy number
Structural variation
SNP-BAF
0
Reference genome sequence
0.5
1
0
1
2
3
4
Reference genome sequence
Detection of copy number alterations
Genuine duplication
Binned read counts
GC-biased WGA
6 6 6 6
2 2
9 9
Copy num ber
Copy number
transformation
with %GC-bias
correction
0
1
2
3
4
Whole-genome
amplification (WGA)
of the cell
-Breadth of genomic coverage
-Allelic drop out (e.g. SNP T/G > T/-)
-Preferential amplification (e.g. SNP T/G > T/GGG)
-Base copying errors
-GC-bias
-Chimeric DNA-molecules
(b)
(c)
(d)
(a)
For reliable single nucleotide variant (SNV) detection in non-haploid single-cell loci: data of at least 2 companion single cells is required,
or deep-sequencing of bulk tumour tissue to distinguish the SNV from a putative base infidelity of the WGA-polymerase 
GC-mediated decrease in focal read-depth not 
confirmed by discordant read-pair
Current Opinion in Genetics & Development
www.sciencedirect.com Current Opinion in Genetics & Development 2014, 24:82–91
86 Cancer genomicsbiopsies of a solid tumour for guiding diagnosis, prognosis
and treatment. Although often just a few CTCs in milli-
litres of peripheral blood of a cancer patient are present,
various isolation techniques based on physical and bio-
logical properties of CTCs have been described [23–25].
However, a main difficulty remains that unbiased CTC-
isolation requires the definition of suitable biomarkers
that are expressed in all blood-borne tumour cells, but
not in normal circulating cells. Similarly, defined
physical and biological properties of DTCs, commonly
homing to the bone marrow, can be used for their
isolation following needle aspiration through the iliac
crest [23,24].
Amplification of single-cell DNA
Modern genomics technologies require hundreds of nano-
grams of input material, while a normal diploid human
cell contains about 7 pg of DNA. Hence, whole-genome
amplification (WGA) is required to enable analysis of a
single cell. WGA of single-cell DNA is based on Multiple
Displacement Amplification (MDA), Polymerase Chain
Reaction (PCR), or a combination of principles of both
displacement amplification and PCR (Figure 2).
Importantly, all amplification methods suffer from various
imperfections that hamper straightforward reliable identi-
fication of genetic variation. The breadth of genomic
coverage, amplification biases (due to local differences
in %GC-content or other factors), the prevalence of
chimeric DNA molecules, allelic drop outs (ADO), pre-
ferential allelic amplifications (PA) and nucleotide copy
errors can differ significantly between different WGA
approaches. As such, some methods are more apt than
others to detect specific genetic variants [26,27,28,29].
In theory, massively parallel sequencing allows profiling
the full spectrum of genetic variation in a cell’s WGA
product, from ploidy changes to aneuploidy and (un)ba-
lanced structural variants, down to indels and base sub-
stitutions. However, the various confounding factors of
WGA complicate this process (Figure 3). A one-fit-all
WGA method remains to be established, and a compara-
tive analysis of all WGA methods against a benchmark
case is acutely needed, assaying the potency of genetic
variation detection, including examining the favourable
effects of the reduction of reaction volumes and ampli-
fication cycles [30].
Despite these dire straits, several groups have proven the
efficacy of single-cell microarray and primarily massively(Figure 3 Legend) Single-cell genome sequencing of cancers. (a) Following
imperfections of current whole-genome amplification (WGA) methods are in
between different WGA methods, hamper straightforward profiling of the ent
the detection of both false-positive and false-negative mutations. (b–d) The
sequencing. Aligning the reads to the human reference genome, followed b
likely genomic changes present in the cell: (b) copy number alterations, (c) 
Current Opinion in Genetics & Development 2014, 24:82–91 parallel sequence analyses to detect multiple classes of
mutation in single tumour cells.
Copy number profiling of single cancer cells
Hybridization of single-cell WGA products to DNA
microarrays or SNP arrays allows uncovering copy number
changes in the cell. SNP arrays provide a distinct
advantage as copy number calls can be integrated with
B allele fractions of SNPs and with genotype calls [31],
thus also allowing the discovery of copy neutral LOH
changes in a cell [32,33], or even to haplotype its entire
genome [34,35]. Despite the use of ultra-high resolution
array platforms and the development of state-of-the-art
computational and statistical methods, the majority of
array-based methods can only reliably detect copy num-
ber changes encompassing millions of bases in a solitary
cell [36,37,38,39]. The main difficulty is to distinguish a
genuine copy number change from a local allelic WGA
artefact due to %GC-bias, ADO or PA events [28]. In
addition, the cell-cycle stage of the isolated cell can
complicate the analysis as cells in S phase can have 2,
3 or 4 copies for a diploid locus, leading to false structural
DNA-imbalance discoveries [40]. Remarkably, a recent
study reported the detection of copy number alterations
as small as 56 kb in single-cell PCR WGA products
hybridized to 180 K oligo-arrays [41].
Array profiling of single cells has been applied to study
the biology of CTCs [42] and DTCs [38,39]. Heitzer
et al. used the technology to profile genetic relationships
between primary colorectal carcinomas, metastases and
CTCs derived from the same patients [42]. Although
CTCs shared a number of gains and losses with the
primary tumour and/or the metastasis, interestingly, they
also observed private copy number changes in CTCs as
well as heterogeneity between CTCs. Such results are
paving the way for using CTCs as a liquid biopsy to guide
clinical decision-making.
Sequencing of single-cell WGA-products recently
improved the resolution of a cell’s DNA-copy number
profile by algorithmic focal sequence-read depth analyses
[16,17,27,43] (Figure 3b). Ni et al. [44] demonstrated
that copy number aberration patterns of CTCs in differ-
ent patients with the same lung cancer subtype can be
extraordinarily similar, but dissimilar when compared to
copy number landscapes of CTCs in patients with differ-
ent lung cancer subtypes, and thus be of diagnostic
significance. Furthermore, driven to understand intra-
tumour cell population structure and genome evolution isolation, single cells are lysed and their DNA is amplified. Various
dicated in the orange box. These imperfections may vary significantly
ire mutation spectrum present in the cell genome wide, and may lead to
 WGA product can be subjected to targeted or full-genome single-cell
y further computation analysis, can subsequently generate a portfolio of
structural variants and (d) single-nucleotide mutations.
www.sciencedirect.com
Single-cell genomics Van Loo and Voet 87in breast cancer, Navin and colleagues [16,17] devel-
oped single-nucleus sequencing for copy number profil-
ing of single cancer cells able to detect alterations with a
resolution of 54 kb on average. By phylogenetic analyses,
they could infer common ancestors, clonal expansions and
divergence of subpopulations.
Structural variant detection in single cells
Genome-wide profiling of structural variation in a single
cell is still in its infancy. Each WGA method likely
fabricates its own characteristic set of chimeric DNA
molecules, which have to be discriminated from bona fide
structural variants following sequencing, a process that is
further complicated by genome coverage issues. There-
fore, currently, many structural variants are still missed by
single-cell genome sequencing. Nevertheless, filters have
been designed to permit the detection of the structural
architecture of copy number alterations following map-
ping of paired-end sequences (Figure 3c) [27] and
approaches to detect L1-retrotransposition have been
developed [45]. In a recent study, we were able to
discover and fine-map intra-chromosomal as well as
inter-chromosomal rearrangements in single cells.
Furthermore, we performed single-cell genome sequen-
cing of individual breast cancer cells related by one cell
cycle, and detected large de novo structural DNA imbal-
ances acquired over one cell division [27], providing
proof of principle that single-cell sequencing can track
tumour evolution in real time.
Detection of point mutations in single cells
Sequencing allows discovering single nucleotide
mutations (Figure 3d). However, genuine base substi-
tutions in the cell have to be discriminated from WGA-
polymerase base infidelities and sequencing errors
[20,26,42,46,47,48,49]. Therefore, reliable single-
nucleotide substitution detection in non-haploid loci
currently necessitates sequencing of multiple single cells
[20,26,46,47,48], or confirmation by deep-sequencing
of matched bulk tissue [42], thus posing problems for
the characterization of rare cell populations.
Targeted sequencing of single-cell WGA products was
recently applied to investigate single-nucleotide
mutations in the exome, to hunt for heterogeneity in a
renal carcinoma [20], a myeloproliferative neoplasm
[46] and a bladder cancer [47]. Although variant calls
of at least three cells had to be considered to filter WGA
and sequencing artefacts from genuine base alterations,
subclonal population structure could be profiled at high
accuracy, providing insight into progression and selection
processes, and understanding of the difficulty of treating
cancer. Single nucleotide and indel mutational land-
scapes in CTCs in patients with lung cancer [44,50]
and colorectal cancer [42,51] were recently also deter-
mined by single-cell exome and cancer gene panel re-
sequencing, respectively. These studies are signalling thewww.sciencedirect.com promise of CTC sequencing for identifying therapeutic
targets and regimens for personalized treatment.
Using short in vitro cultures, mutation rates have been
tracked over a limited amount of cell divisions. Whole-
genome sequencing of multiple WGAed cells revealed a
base mutation rate in a colorectal adenocarcinoma cell
line that was 10-fold higher when compared to estimates
of germline studies [26].
Altogether, despite current limitations, massively parallel
sequencing of single cells revealed a dynamic picture of
on-going genetic evolution and clonal expansion in can-
cer, and is delivering genomic snapshots of rare tumour
cells, such as CTCs and DTCs, and thus new insight in
the disease.
Single-cell transcriptomics
Following single-cell isolation, the epigenome and the
transcriptome may also be studied [21]. While epige-
nomics of single cells remains challenging [52–55],
methods for single-cell transcriptomics have flourished
(Figure 4) and delivered baffling new insight into
the (functional) heterogeneity of cell populations
[56–58].
A single cell contains less than 1 pg of mRNA. To
characterize it via array [59,60] or sequencing [56–58]
approaches, whole-transcriptome amplification (WTA)
is required. Methods for WTA are grounded on PCR-
based [61–64,65,66–69], MDA-based [67] or in vitro
transcription (IVT)-based [70] amplification of reverse
transcribed single-cell mRNA, whereby IVT likely
results in a more linear amplification. However, WTA
and subsequent analysis methods struggle with reliable
amplification and detection of transcripts expressed at
less than 10 copies per cell. In addition, the majority of
the methods only selectively amplify the polyadeny-
lated RNAs of a cell’s transcript repertoire [61–
64,65,66,70], and may be biased to the 30-end [70] or
the 50-end [61,62] of a transcript (Figure 4). Full-length
mRNA-characterization from a single cell can only be
achieved by a few WTA-methods [63,64,65,66,67,68]
(Figure 4).
To the best of our knowledge, no large-scale single cancer
cell transcriptome sequencing studies have been
reported, although this is on the horizon [71–73]. In a
recent elegant proof-of-principle experiment, Ramsko¨ld
et al. found differences between melanoma CTCs and
primary melanocytes, giving insight into the disease [65].
Additionally, the technology allowed defining potent
plasma membrane CTC biomarkers and discovering
expressed coding mutations. This and other studies
[60,73–75] show that single-cell transcriptomics will illu-
minate further insights into oncogenesis, tumour subclo-
nal architecture and cell lineage diversity.Current Opinion in Genetics & Development 2014, 24:82–91
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Single-cell transcriptome sequencing of cancers. Following isolation, single cells are lysed and their mRNA is amplified using whole-transcriptome
amplification (WTA) techniques. At the moment, still various imperfections of the single-cell WTA process, which are indicated in orange, hamper
profiling of the entire transcriptome of a cell. Single-cell transcriptomics allows illuminating heterogeneity in gene expression and transcript splicing.
Furthermore, single-cell RNA sequencing may be applied for discovering expressed fusion genes and coding mutations.Single-cell sequencing studies currently only process
either WGA-products or WTA-products of a cell,
although protocols for combined approaches are under
development [76,77]. The ability to profile both the
genome and the transcriptome of the same cell has
enormous potential to elucidate heterogeneity at the
genome, epigenome and transcriptome level. In addition,
such techniques would allow mutations of the genome in
a single cell to be confirmed in that cell’s transcriptome,
opening avenues to detect mutations at high confidence,
even if they are observed only in one single cell.
Perspectives for cancer research and
treatment
The emerging field of single cell genomics opens new
avenues that may have far-reaching implications for can-
cer research and clinical practice. It allows characteriz-
ation of intra-tumour genetic heterogeneity genome-wideCurrent Opinion in Genetics & Development 2014, 24:82–91 to single-cell resolution, and thereby offers a unique
viewpoint into tumour evolution. Current single-cell
sequencing studies have focused on only tens to hundreds
of cells, but already revealed complex heterogeneity at
this level. We envisage that the scale of these exper-
iments will increase impressively in the coming years.
Emergence of microfluidics systems, able to generate
sequencing-ready libraries for thousands to millions of
individual cells in parallel is likely. Such methods, as well
as massive single-cell genotyping assays [78], combined
with clever bioinformatics approaches to infer relation-
ships and life histories of individual cells, will provide
detailed insight into the emergence and clonal expansion
of each tumour subclone, allowing a truly holistic view on
tumour evolution.
Little is known about the variability in the epigenome
and the transcriptome of single cells, as this is masked inwww.sciencedirect.com
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envisage that future methods that can profile the (epi)-
genome and the transcriptome of the same single cell will
allow detailed insights into the transcriptional and phe-
notypic consequences of genomic changes in cancer.
Finally, by sequencing individual CTCs and DTCs
together with primary tumour cells and metastases, we
will learn more about the mechanisms that trigger single
tumour cells to leave the site of their origin, the dormancy
of DTCs and their resistance to cancer therapy. We
anticipate that partial or full cancer genomes of (fine-
needle) cancer biopsies, CTCs and/or DTCs will routi-
nely be sequenced as part of the clinical evaluation and
likely personalized treatments in the future. CTCs may
be particularly important in this regard as they represent
easily obtainable liquid biopsies allowing real-time
monitoring of both metastatic potential and patient-
specific suitability of therapy.
Conclusions
The last few years have seen rapid development of
technologies that permit detailed analysis of the genomes
and transcriptomes of single cells. Single-cell approaches
now stand poised to provide an unprecedented view into
cancer evolution.
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